WA
www.a2i-tx.com
InactiveThe startup develops small-molecule immuno-oncology agents that target a key protein involved in the innate immune response, utilizing an artificial intelligence platform for therapeutic design. This approach aims to enhance treatment efficacy for immuno-oncology diseases, addressing the need for more effective therapies in oncology.
Traction –/10
HQ unknown
- Artificial Intelligence
- Biotechnology
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small-molecule immuno-oncology agents that target a key protein involved in the innate immune response, utilizing an artificial intelligence platform for therapeutic design. This approach aims to enhance treatment efficacy for immuno-oncology diseases, addressing the need for more effective therapies in oncology.